1
|
Beijert IJ, Cheng L, Liedberg F, Plass K, Williamson SR, Gontero P, Ribal MJ, Babjuk M, Black PC, Kamat AM, Algaba F, Berman DM, Hartmann A, Masson-Lecomte A, Rouprêt M, Lopez-Beltran A, Samaratunga H, Shariat SF, Mostafid AH, Varma M, Shen S, Burger M, Tsuzuki T, Palou J, Compérat EM, Sylvester RJ, van der Kwast TH, van Rhijn BW, Downes MR. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members. EUR UROL SUPPL 2023; 52:154-165. [PMID: 37284047 PMCID: PMC10240524 DOI: 10.1016/j.euros.2023.03.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/29/2023] [Indexed: 06/08/2023] Open
Abstract
Background Grade of non-muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1-3, and WHO2004 categories: papillary urothelial neoplasm of low malignant potential [PUNLMP], low-grade [LG], high-grade [HG] carcinoma) are used. Objective To ask the European Association of Urology (EAU) and International Society of Urological Pathology (ISUP) members regarding their current practice and preferences of grading systems. Design setting and participants A web-based, anonymous questionnaire with ten questions on grading of NMIBC was created. The members of EAU and ISUP were invited to complete an online survey by the end of 2021. Thirteen experts had previously answered the same questions. Outcome measurements and statistical analysis The submitted answers from 214 ISUP members, 191 EAU members, and 13 experts were analyzed. Results and limitations Currently, 53% use only the WHO2004 system and 40% use both systems. According to most respondents, PUNLMP is a rare diagnosis with management similar to Ta-LG carcinoma. The majority (72%) would consider reverting back to WHO1973 if grading criteria were more detailed. Separate reporting of WHO1973-G3 within WHO2004-HG would influence clinical decisions for Ta and/or T1 tumors according the majority (55%). Most respondents preferred a two-tier (41%) or a three-tier (41%) grading system. The current WHO2004 grading system is supported by a minority (20%), whereas nearly half (48%) supported a hybrid three- or four-tier grading system composed of both WHO1973 and WHO2004. The survey results of the experts were comparable with ISUP and EAU respondents. Conclusions Both the WHO1973 and the WHO2004 grading system are still widely used. Even though opinions on the future of bladder cancer grading were strongly divided, there was limited support for WHO1973 and WHO2004 in their current formats, while the hybrid (three-tier) grading system with LG, HG-G2, and HG-G3 as categories could be considered the most promising alternative. Patient summary Grading of non-muscle-invasive bladder cancer (NMIBC) is a matter of ongoing debate and lacks international consensus. We surveyed urologists and pathologists of European Association of Urology and International Society of Urological Pathology on their preferences regarding NMIBC grading to generate a multidisciplinary dialogue. Both the "old" World Health Organization (WHO) 1973 and the "new" WHO2004 grading schemes are still used widely. However, continuation of both the WHO1973 and the WHO2004 system showed limited support, while a hybrid grading system composed of both the WHO1973 and the WHO2004 classification system may be considered a promising alternative.
Collapse
Affiliation(s)
- Irene J. Beijert
- Department of Surgical Oncology (Urology), Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands
| | - Liang Cheng
- Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center and Legorreta Cancer Center at Brown University, Providence, RI, USA
| | - Fredrik Liedberg
- Department of Translational Medicine, Lund University, Malmö, Sweden
- Department of Urology, Skåne University Hospital, Malmö, Sweden
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
| | - Karin Plass
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands
| | | | - Paolo Gontero
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
| | - Maria J. Ribal
- European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands
- Department of Urology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - Marko Babjuk
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
| | - Peter C. Black
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Ashish M. Kamat
- Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - Ferran Algaba
- Department of Pathology, Fundació Puigvert, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - David M. Berman
- Kingston Health Sciences Centre, Queen’s University, Kingston, ON, Canada
- Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada
| | - Arndt Hartmann
- Institute of Pathology, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
| | - Alexandra Masson-Lecomte
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Université de Paris, APHP, Saint Louis Hospital, Paris, France
| | - Morgan Rouprêt
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Pitié Salpétrière Hospital, AP-HP, GRC n°5, ONCOTYPE-URO, Sorbonne University, Paris, France
| | - Antonio Lopez-Beltran
- Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain
- Anatomic Pathology, Champalimaud Clinical Center, Lisbon, Portugal
| | - Hemamali Samaratunga
- Department of Pathology, Aquesta Uropathology and University of Queensland, Brisbane, Australia
| | - Shahrokh F. Shariat
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
| | - A. Hugh Mostafid
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK
| | - Murali Varma
- Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK
| | - Steven Shen
- Department of Pathology Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA
| | - Maximilian Burger
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
| | - Toyonori Tsuzuki
- Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
| | - Joan Palou
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Eva M. Compérat
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Pathology, Medical University Vienna, Vienna General Hospital, Vienna, Austria
| | - Richard J. Sylvester
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
| | - Theo H. van der Kwast
- Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada
| | - Bas W.G. van Rhijn
- Department of Surgical Oncology (Urology), Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
| | - Michelle R. Downes
- Division of Anatomic Pathology, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
2
|
von Deimling M, Mertens LS, van Rhijn BW, Lotan Y, Spiess PE, Daneshmand S, Black PC, Pallauf M, D'Andrea D, Moschini M, Soria F, Del Giudice F, Afferi L, Laukhtina E, Yanagisawa T, Kawada T, Teoh JYC, Abufaraj M, Ploussard G, Roumiguié M, Karakiewicz PI, Babjuk M, Gontero P, Xylinas E, Rink M, Shariat SF, Pradere B. Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer. EUR UROL SUPPL 2023; 51:39-46. [PMID: 37187719 PMCID: PMC10175724 DOI: 10.1016/j.euros.2023.02.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/23/2023] [Indexed: 03/28/2023] Open
Abstract
Background There are currently no guideline recommendations regarding the treatment of cisplatin-ineligible, clinically lymph node-positive (cN+) bladder cancer (BCa). Objective To investigate the oncological efficacy of gemcitabine/carboplatin induction chemotherapy (IC) in comparison to cisplatin-based regimens in cN+ BCa. Design setting and participants This was an observational study of 369 patients with cT2-4 N1-3 M0 BCa. Intervention IC followed by consolidative radical cystectomy (RC). Outcome measurements and statistical analysis The primary endpoints were the pathological objective response (pOR; ypT0/Ta/Tis/T1 N0) rate and the pathological complete response (pCR; ypT0N0) rate. We applied 3:1 propensity score matching (PSM) to reduce selection bias. Overall survival (OS) and cancer-specific survival (CSS) were compared across groups using the Kaplan-Meier method. Associations between the treatment regimen and survival endpoints were tested in multivariable Cox regression analyses. Results and limitations After PSM, a cohort of 216 patients was available for analysis, of whom 162 received cisplatin-based IC and 54 gemcitabine/carboplatin IC. At RC, 54 patients (25%) had a pOR and 36 (17%) had a pCR. The 2-yr CSS was 59.8% (95% confidence interval [CI] 51.9-69%) for patients who received cisplatin-based IC versus 38.8% (95% CI 26-57.9%) for those who received gemcitabine/carboplatin. For the pOR (p = 0.8), ypN0 status at RC (p = 0.5), and cN1 BCa subgroups (p = 0.7), there was no difference in CSS between cisplatin-based IC and gemcitabine/carboplatin. In the cN1 subgroup, treatment with gemcitabine/carboplatin was not associated with shorter OS (p = 0.2) or CSS (p = 0.1) on multivariable Cox regression analysis. Conclusions Cisplatin-based IC seems to be superior to gemcitabine/carboplatin and should be the standard for cisplatin-eligible patients with cN+ BCa. Gemcitabine/carboplatin may be an alternative treatment for selected cisplatin-ineligible patients with cN+ BCa. In particular, selected cisplatin-ineligible patients with cN1 disease may benefit from gemcitabine/carboplatin IC. Patient summary In this multicenter study, we found that selected patients with bladder cancer and clinical evidence of lymph node metastasis who cannot receive standard cisplatin-based chemotherapy before surgery to remove their bladder may benefit from chemotherapy with gemcitabine/carboplatin. Patients with a single lymph node metastasis may benefit the most.
Collapse
|
3
|
Mertens LS, Sharma V, Matin SF, Boorjian SA, Houston Thompson R, van Rhijn BW, Masson-Lecomte A. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies. EUR UROL SUPPL 2023; 49:60-66. [PMID: 36793750 PMCID: PMC9922921 DOI: 10.1016/j.euros.2023.01.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/10/2023] [Indexed: 01/29/2023] Open
Abstract
Context Bladder recurrences have been reported in 22-47% of patients after surgery for upper urinary tract urothelial carcinoma (UTUC). This collaborative review focuses on risk factors for and treatment strategies to reduce bladder recurrences after upper tract surgery for UTUC. Objective To review the current evidence on risk factors and treatment strategies for intravesical recurrence (IVR) after upper tract surgery for UTUC. Evidence acquisition This collaborative review is based on a literature search of PubMed/Medline, Embase, Cochrane Library, and currently available guidelines on UTUC. Relevant papers on bladder recurrence (etiology, risk factors, and management) after upper tract surgery were selected. Special attention has been paid to (1) the genetic background of bladder recurrences, (2) bladder recurrences after ureterorenoscopy (URS) with or without a biopsy, and (3) postoperative or adjuvant intravesical instillations. The literature search was performed in September 2022. Evidence synthesis Recent evidence supports the hypothesis that bladder recurrences after upper tract surgery for UTUC are often clonally related. Clinicopathologic risk factors (patient, tumor, and treatment related) have been identified for bladder recurrences after UTUC diagnosis. Specifically, the use of diagnostic ureteroscopy before radical nephroureterectomy (RNU) is associated with an increased risk of bladder recurrences. Further, a recent retrospective study suggests that performing a biopsy during ureteroscopy may further worsen IVR (no URS: 15.0%; URS without biopsy: 18.4%; URS with biopsy: 21.9%). Meanwhile, a single postoperative instillation of intravesical chemotherapy has been shown to be associated with a reduced bladder recurrence risk after RNU compared with no instillation (hazard ratio 0.51, 95% confidence interval 0.32-0.82). Currently, there are no data on the value of a single postoperative intravesical instillation after ureteroscopy. Conclusions Although based on limited retrospective data, performing URS seems to be associated with a higher risk of bladder recurrences. Future studies are warranted to assess the influence of other surgical factors as well as the role of URS biopsy or immediate postoperative intravesical chemotherapy after URS for UTUC. Patient summary In this paper, we review recent findings on bladder recurrences after upper tract surgery for upper urinary tract urothelial carcinoma.
Collapse
Affiliation(s)
- Laura S. Mertens
- Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands,Corresponding author. Department of Urology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel. +31 20 512 2553.
| | - Vidit Sharma
- Department of Urology, Mayo Clinic, Rochester, MN, USA
| | - Surena F. Matin
- Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | | | - Bas W.G. van Rhijn
- Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands,Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany
| | | |
Collapse
|
4
|
Einerhand SM, Voskuilen CS, van de Putte EEF, Donswijk ML, Bruining A, van der Heijden MS, Mertens LS, Hendricksen K, Vegt E, van Rhijn BW. Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer. Bladder Cancer 2022. [DOI: 10.3233/blc-220036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND: Neoadjuvant/induction chemotherapy (NAIC) improves survival in patients with muscle-invasive bladder carcinoma (MIBC). On-treatment response assessment may aid in decisions to continue or cease NAIC. OBJECTIVE: We investigated whether 18F-fluoro-2-deoxy-D-glucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) could predict response to NAIC and compared to contrast-enhanced Computed Tomography (CECT). METHODS: We prospectively included 83 patients treated for MIBC (i.e. high-risk cT2-4N0M0 or cT1-4N+M0-1a) between 2014 and 2018. Response to NAIC was assessed after 2-3 cycles with FDG-PET/CT (Peter-Mac and EORTC criteria) and CECT (RECIST1.1 criteria). We assessed prediction of complete pathological response (pCR; ypT0N0), complete pathological down-staging (pCD;≤ypT1N0), any down-staging from baseline (ypTN < cTN) and progression (inoperable tumor/ypN+/M+). The reference standard was histopathological assessment or clinical follow-up. Sensitivity, specificity, and accuracy were calculated. RESULTS: Pathological response rates were 21% for pCR, 29% for pCD, and 10% progressed. All patients underwent FDG-PET/CT and 61 patients also underwent CECT (73%). Accuracy of FDG-PET/CT for prediction of pCR, pCD, and progression were 73%, 48%, and 73%, respectively. Accuracy of CECT for prediction of pCR, pCD, and progression were 78%, 65%, and 67%, respectively. Specificity of CECT was significantly higher than FDG-PET/CT for prediction of pCD and any down-staging (p = 0.007 and p = 0.022). In all other analyses, no significant differences between FDG-PET/CT and CECT were found. CONCLUSIONS: Routine FDG-PET/CT has insufficient predictive power to aid in response assessment compared to CECT.
Collapse
Affiliation(s)
- Sarah M.H. Einerhand
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands
| | - Charlotte S. Voskuilen
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands
| | | | - Maarten L. Donswijk
- Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Annemarie Bruining
- Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Michiel S. van der Heijden
- Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Laura S. Mertens
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands
| | - Kees Hendricksen
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands
| | - Erik Vegt
- Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Bas W.G. van Rhijn
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands
- Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
| |
Collapse
|
5
|
de Vries HM, Ottenhof SR, Rafael TS, van Werkhoven E, Pos FJ, van Rhijn BW, Moonen LM, Graafland N, de Feijter JM, Schaake EE, Horenblas S, Brouwer OR. Patterns of Recurrence and Survival After Pelvic Treatment for Locally Advanced Penile Cancer. EUR UROL SUPPL 2022; 47:29-35. [PMID: 36601037 PMCID: PMC9806705 DOI: 10.1016/j.euros.2022.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/11/2022] [Indexed: 12/23/2022] Open
Abstract
Background Penile cancer (PeCa) is rare, and the survival of patients with advanced disease remains poor. A better understanding of where treatment fails could aid the development of new treatment strategies. Objective To describe the disease course after pelvic lymph node (LN) treatment for PeCa. Design setting and participants We retrospectively analysed 228 patients who underwent pelvic LN treatment with curative intent from 1969 to 2016. The main treatment modalities were neoadjuvant chemotherapy, chemoradiation, and pelvic LN dissection. Outcome measurements and statistical analysis In the case of multiple recurrence locations, the most distant location was taken and recorded as follows: local (penis), regional (inguinal and pelvic LN), and distant (any other location). A competing risk analysis was used to calculate the time to recurrence per location, and a Kaplan-Meier analysis was used for overall survival (OS). Results and limitations The median follow-up of the surviving patients was 79 mo. The reason for pelvic treatment was pelvic involvement on imaging (29%), two or more tumour-positive inguinal LNs (61%), or inguinal extranodal extension (52%). More than half of the patients (61%) developed a recurrence. The median recurrence-free survival was 11 mo. The distribution was local in 9%, regional in 27%, and distant in 64% of patients. The infield control rate of nonsystemically treated patients was 61% (113/184). From the start of pelvic treatment, the median OS was 17 mo (95% confidence interval 12-22). After regional or distant recurrence, all but one patient died of PeCa with median OS after a recurrence of 4.4 (regional) and 3.1 (distant) mo. This study is limited by its retrospective nature. Conclusions The prognosis of PeCa patients treated on their pelvis who recur despite locoregional treatment is poor. The tendency for systemic spread emphasises the need for more effective systemic treatment strategies. Patient summary In this report, we looked at the outcomes of penile cancer patients in an expert centre undergoing various treatments on their pelvis. We found that survival is poor after recurrence despite locoregional treatment. Therefore, better systemic treatments are necessary.
Collapse
Affiliation(s)
- Hielke M. de Vries
- Department of Urology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Sarah R. Ottenhof
- Department of Urology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Tynisha S. Rafael
- Department of Urology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Erik van Werkhoven
- Department of Biostatistics, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Floris J. Pos
- Department of Radiation therapy, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Bas W.G. van Rhijn
- Department of Urology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Luc M.F. Moonen
- Department of Radiation therapy, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Niels Graafland
- Department of Urology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Jeantine M. de Feijter
- Department of Internal Medicine, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Eva E. Schaake
- Department of Radiation therapy, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Simon Horenblas
- Department of Urology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Oscar R. Brouwer
- Department of Urology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands,Corresponding author. Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel. +31205129111; Fax: +31205129111.
| |
Collapse
|
6
|
van Hoogstraten LM, Witjes JA, Meijer RP, Ripping TM, Kiemeney LA, Aben KK, de Reijke TM, Goossens‐Laan CA, Hulshof MC, van Leenders GJ, Leliveld AM, Mulder SF, Noteboom JL, Oddens JR, Smilde TJ, Venderbosch GW, van der Heijden AG, van der Heijden MS, van Moorselaar RJ, van Rhijn BW, van Roermund JG, Wijsman BP. Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent. BJU Int 2022; 130:764-775. [PMID: 35064953 PMCID: PMC9790563 DOI: 10.1111/bju.15697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 11/26/2021] [Accepted: 01/14/2022] [Indexed: 12/30/2022]
Abstract
OBJECTIVES To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND METHODS For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). RESULTS One-third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. CONCLUSION On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
Collapse
Affiliation(s)
- Lisa M.C. van Hoogstraten
- Netherlands Comprehensive Cancer OrganizationUtrechtthe Netherlands,Radboud Institute for Health SciencesRadboud University Medical CentreNijmegenthe Netherlands
| | - J. Alfred Witjes
- Department of UrologyRadboud University Medical CentreNijmegenthe Netherlands
| | - Richard P. Meijer
- Department of Oncological UrologyUniversity Medical Centre UtrechtUtrechtthe Netherlands
| | | | | | - Lambertus A. Kiemeney
- Radboud Institute for Health SciencesRadboud University Medical CentreNijmegenthe Netherlands,Department of UrologyRadboud University Medical CentreNijmegenthe Netherlands
| | - Katja K.H. Aben
- Netherlands Comprehensive Cancer OrganizationUtrechtthe Netherlands,Radboud Institute for Health SciencesRadboud University Medical CentreNijmegenthe Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Habibi K, Tirdad K, Dela Cruz A, Wenger K, Mari A, Basheer M, Kuk C, van Rhijn BW, Zlotta AR, van der Kwast TH, Sadeghian A. ABC: Artificial Intelligence for Bladder Cancer grading system. Machine Learning with Applications 2022. [DOI: 10.1016/j.mlwa.2022.100387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
8
|
Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seilerd R, Black PC, Boormans JL, Dall'Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BW, van der Heijden MS, Hsiehc AC, Wrighta JL, Lam HM. Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 2022; 40:352. [DOI: 10.1016/j.urolonc.2022.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Wenger K, Tirdad K, Dela Cruz A, Mari A, Mayada Basheer, Kuk C, van Rhijn BW, Zlotta AR, van der Kwast TH, Sadeghian A. A semi-supervised learning approach for bladder cancer grading. Machine Learning with Applications 2022. [DOI: 10.1016/j.mlwa.2022.100347] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
10
|
Roghmann F, Goebell PJ, Dyrskjøt L, van Rhijn BW, Käfferlein HU, Hakenberg O, Stenzl A, Burger M, Pesch B, Benderska-Söder N, Schmitz-Dräger BJ. Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple? Bladder Cancer 2021. [DOI: 10.3233/blc-211602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Marker research and, in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing and editorial efforts) and financial resources finally generating large numbers of manuscripts without affecting clinical decision making. This is mirrored by the fact that current guidelines do not recommend marker use due to missing level 1 evidence. Although we recognize the problems and obstacles, the authors of this commentary feel that the time has come to abandon the current procedures and move on to prospective trial designs implementing marker results into clinical decision making. Our thoughts and concerns are summarized in this comment.
Collapse
Affiliation(s)
- Florian Roghmann
- Department of Urology, Marienhospital Herne, Ruhr-University, Bochum, Germany
| | - Peter J. Goebell
- Department of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany
| | - Lars Dyrskjøt
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Bas W.G. van Rhijn
- Department of Surgical Oncology, Division of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Heiko U. Käfferlein
- Institute for Prevention and Occupational Medicine of the German Social Accidence Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany
| | | | - Arnulf Stenzl
- Department of Urology, Eberhard-Karls-University of Tübingen, Tübingen, Germany
| | - Maximilian Burger
- Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
| | | | | | - Bernd J. Schmitz-Dräger
- Department of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany
- Urologie 24, Nürnberg, Germany
| |
Collapse
|
11
|
Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ, Marks P, Saba K, van Rhijn BW, Fransen van de Putte EE, Ablat J, Black PC, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto JW, Xylinas E, Hendricksen K. Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. Eur Urol Focus 2020; 6:1226-1232. [DOI: 10.1016/j.euf.2018.12.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 11/27/2018] [Accepted: 12/04/2018] [Indexed: 02/07/2023]
|
12
|
de Jong JJ, Liu Y, Seiler R, Robertson AG, van der Heijden MS, Wright JL, Douglas J, Dall'Era M, Crabb SJ, van Rhijn BW, van Kessel KE, Davicioni E, Lotan Y, Zwarthoff EC, Black PC, Boormans JL, Gibb EA. Abstract B07: A long noncoding RNA-based genomic classifier identifies a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.bladder19-b07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease and gene expression profiling has identified different molecular subtypes, each having distinct biologic and clinicopathologic characteristics. Subtyping MIBC has primarily been messenger RNA (mRNA)-based, although noncoding RNAs, including long noncoding RNAs (lncRNAs), have potential utility in providing additional resolution to current molecular subtyping models.
Materials and Methods: The expression profiles of over 6,000 lncRNAs were quantified from whole-transcriptome microarray data of a MIBC patient cohort treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (N=223). Unsupervised consensus clustering of the most highly variant lncRNAs identified a four-cluster solution, which was further characterized using a panel of MIBC biomarkers, gene signatures, and survival analysis. The four-cluster consensus was validated using the publicly available The Cancer Genome Atlas (TCGA) radical cystectomy cohort (N=405). A single-sample genomic classifier (GC) was trained using ridge-penalized logistic regression and then validated in two independent patient cohorts (N=255 and N=94).
Results: In the NAC and TCGA cohorts, survival analysis of a lncRNA-based consensus cluster solution revealed a lncRNA-cluster (LC3) with strikingly good prognosis that was enriched for tumors of the luminal-papillary mRNA subtype. In both cohorts, the luminal-papillary tumors from this cluster (LPL-C3) were clinically less aggressive than other luminal-papillary tumors. Patients having LPL-C3 tumors were younger and had more frequent organ-confined, node-negative disease than other luminal-papillary tumors. LPL-C3 tumors were characterized by enhanced FGFR3 pathway activity, wild-type P53 expression, and robust SHH signaling. In the TCGA cohort, LPL-C3 tumors were also enriched for FGFR3 mutations and depleted for TP53 and RB1 mutations. A GC trained to identify these LPL-C3 patients showed robust performance in two validation cohorts.
Conclusions: Using lncRNA expression profiling, we identified a biologically distinct subgroup of luminal-papillary MIBC with less-aggressive molecular characteristics and favorable prognosis. These data suggest that lncRNAs can provide additional information in resolving higher-resolution subtypes for more precise patient management strategies.
Citation Format: Joep J. de Jong, Yang Liu, Roland Seiler, A. Gordon Robertson, Michiel S. van der Heijden, Jonathan L. Wright, James Douglas, Marc Dall'Era, Simon J. Crabb, Bas W.G. van Rhijn, Kim E.M. van Kessel, Elai Davicioni, Yair Lotan, Ellen C. Zwarthoff, Peter C. Black, Joost L. Boormans, Ewan A. Gibb. A long noncoding RNA-based genomic classifier identifies a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2019 May 18-21; Denver, CO. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(15_Suppl):Abstract nr B07.
Collapse
Affiliation(s)
| | - Yang Liu
- 2GenomeDx Biosciences, Vancouver, BC, Canada,
| | | | | | | | | | - James Douglas
- 7University Hospital of Southampton, Hampshire, United Kingdom,
| | - Marc Dall'Era
- 8UC Davis Comprehensive Cancer Center, Sacramento, CA,
| | - Simon J. Crabb
- 7University Hospital of Southampton, Hampshire, United Kingdom,
| | | | | | | | - Yair Lotan
- 9UT Southwestern Medical Center, Dallas, TX,
| | | | | | | | | |
Collapse
|
13
|
D’Andrea D, Foerster B, Matin SF, Ku JH, Muilwijk T, Monteiro LL, Liao R, Petros FG, Spiess PE, Bivalacqua TJ, Hendricksen K, van Rhijn BW, Shabsigh A, Briganti A, Joniau S, Kassouf W, Pierorazio PM, Margulis V, Necchi A, Shariat SF. Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. EUR UROL SUPPL 2020; 19:16-19. [PMID: 34337449 PMCID: PMC8317786 DOI: 10.1016/j.euros.2020.04.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/22/2020] [Indexed: 11/21/2022] Open
Affiliation(s)
- David D’Andrea
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - Beat Foerster
- Department of Urology, Medical University of Vienna, Vienna, Austria
- Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland
| | - Surena F. Matin
- Department of Urology, MD Anderson Cancer Center, Houston, TX, USA
| | - Ja H. Ku
- Department of Urology, Seoul National University Hospital, Seoul, South Korea
| | - Tim Muilwijk
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - Leonardo L. Monteiro
- Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada
| | - Ross Liao
- Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Firas G. Petros
- Department of Urology and Kidney Transplant, The University of Toledo Medical Center and Eleanor N. Dana Cancer Center, Toledo, OH, USA
| | - Philippe E. Spiess
- Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Trinity J. Bivalacqua
- Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Kees Hendricksen
- Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Bas W.G. van Rhijn
- Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Ahmad Shabsigh
- Department of Urology, Ohio State University, Columbus, OH, USA
| | - Alberto Briganti
- Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
| | - Steven Joniau
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - Wassim Kassouf
- Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada
| | - Phillip M. Pierorazio
- Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Vitaly Margulis
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Andrea Necchi
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Shahrokh F. Shariat
- Department of Urology, Medical University of Vienna, Vienna, Austria
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
- Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- Department of Urology, Weill Cornell Medical College, New York, NY, USA
- Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
- Department of Urology, University of Jordan, Amman, Jordan
- Corresponding author. Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Tel.: +43 1 404002615; Fax: +43 1 404002332.
| | | |
Collapse
|
14
|
Van Dijk N, Gil Jimenez A, Silina K, Hendricksen K, Smit L, De Feijter J, van Montfoort ML, Broeks A, Lubeck Y, Sikorska K, Boellaard TN, Kvistborg P, Vis DJ, Hooijberg E, Schumacher T, van den Broek M, Wessels LFA, Blank CU, van Rhijn BW, Van Der Heijden MS. Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.5020] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5020 Background: Encouraging pathological complete response (pCR) rates were observed in trials testing neoadjuvant pembrolizumab or atezolizumab in urothelial cancer (UC). In cT3-4N0 tumors, pCR to atezolizumab was only 17% and restricted to tumors showing characteristics of preexisting T cell immunity. In NABUCCO, we aimed to increase response to pre-operative checkpoint blockade, particularly in high risk patients (pts), by combining ipi plus nivo in stage III UC. We previously reported pCR in 46% and downstaging to no remaining invasive disease in 58% (ESMO2019). Here, we present biomarker analyses and updated clinical follow-up (FU) data. Methods: Twenty four stage III (cT3-4aN0 or cT2-4aN1-3) UC pts who were unfit to receive cisplatin-based chemotherapy or refused, were treated with ipi 3 mg/kg (day 1), ipi 3 mg/kg + nivo 1 mg/kg (day 22), and nivo 3 mg/kg (day 43), followed by resection. The primary endpoint was feasibility (resection < 12 weeks). Efficacy (pCR), safety and biomarker analysis were secondary endpoints. Whole-exome sequencing (WES) was done on baseline tumor samples and local lymph node (LN) metastases showing no response. RNA-seq and multiplex immunofluorescence (mIF) for immune cell markers were done pre- and post-therapy. Results: After a median FU of 15.6 months, 2 pts relapsed (both non-pCR); 1 of these 2 pts died of metastatic disease. Tumors showing complete response (CR, for biomarker analysis defined as pCR, CIS or pTa) had a significantly higher tumor mutational burden than non-CR tumors. CR to ipi+nivo was independent of baseline CD8 T-cell presence. There was no difference between CR and non-CR tumors in baseline immune gene signatures, such as interferon gamma and T-effector signatures. Surprisingly, exploratory gene expression analysis revealed that non-CR was associated with a baseline B cell immune signature, particularly immunoglobulins and genes involved in B cell receptor signaling. CD20 positive cells (by mIF) and presence of tertiary lymphoid structures (TLS) at baseline were also associated with non-CR. Upon treatment with ipi+nivo, early and mature TLS increased significantly in responding tumors. A subset of pts showed CR in the bladder, but non-CR in a local LN tumor focus. WES revealed that these LN metastases were genetically different from the primary tumor bulk. Conclusions: At 15.6 months follow-up, recurrence after pre-operative ipi+nivo was low. Pathological complete response was not restricted to tumors exhibiting preexisting T cell immunity. Clinical trial information: NCT03387761 .
Collapse
Affiliation(s)
- Nick Van Dijk
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Alberto Gil Jimenez
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Karina Silina
- Institute of Experimental Immunology, University Hospital Zurich, Zurich, Switzerland
| | - Kees Hendricksen
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Laura Smit
- Netherlands Cancer Institute (NKI-AVL), Amsterdam, Netherlands
| | | | | | | | - Yoni Lubeck
- Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Karolina Sikorska
- Department of Statistics, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | | | - Pia Kvistborg
- The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands
| | - Daniel J Vis
- Netherlands Cancer Institute, Amsterdam, Netherlands
| | | | - Ton Schumacher
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | | | | | | | - Bas W.G. van Rhijn
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | | |
Collapse
|
15
|
Hentschel AE, van Rhijn BW, Bründl J, Compérat EM, Plass K, Rodríguez O, Henríquez JDS, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Bruins HM, Runneboom W, Herdegen S, Breyer J, Brisuda A, Scavarda-Lamberti A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VR, Ashabere D, Huebner N, Cotte J, Mertens LS, Cohen D, Lunelli L, Cussenot O, Sheikh SE, Volanis D, Coté JF, Rouprêt M, Haitel A, Shariat SF, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, Kiemeney LA, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Babjuk M, van der Kwast TH, Sylvester RJ. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Urol Oncol 2020; 38:440-448. [DOI: 10.1016/j.urolonc.2019.10.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 09/23/2019] [Accepted: 10/02/2019] [Indexed: 12/21/2022]
|
16
|
Mertens LS, Behrendt MA, Mehta AM, Stokkel L, de Jong J, Boot H, Horenblas S, van der Heijden MS, Moonen LM, Aalbers AG, Meinhardt W, van Rhijn BW. Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer. Eur J Surg Oncol 2019; 45:1740-1744. [DOI: 10.1016/j.ejso.2019.03.034] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 03/14/2019] [Accepted: 03/26/2019] [Indexed: 11/24/2022] Open
|
17
|
Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall’Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BW, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res 2019; 25:3908-3920. [DOI: 10.1158/1078-0432.ccr-18-3558] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 01/21/2019] [Accepted: 03/26/2019] [Indexed: 11/16/2022]
|
18
|
Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, Maclennan S, N’dow J, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Mostafid H, van Rhijn BW, Gontero P, Palou J, Shariat SF, Roupret M. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. Eur Urol Focus 2019; 5:205-223. [DOI: 10.1016/j.euf.2017.10.003] [Citation(s) in RCA: 79] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Revised: 08/10/2017] [Accepted: 10/10/2017] [Indexed: 01/16/2023]
|
19
|
Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BW, Hartmann A, Catto JW, Kulkarni GS. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. Eur Urol 2018; 74:597-608. [DOI: 10.1016/j.eururo.2018.06.024] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Accepted: 06/20/2018] [Indexed: 10/28/2022]
|
20
|
Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BW, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Cancer Res 2018; 25:5082-5093. [DOI: 10.1158/1078-0432.ccr-18-1106] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Revised: 08/08/2018] [Accepted: 09/11/2018] [Indexed: 11/16/2022]
|
21
|
Bosschieter J, Vis AN, van der Poel HG, Moonen LM, Horenblas S, van Rhijn BW, Pieters BR, Nieuwenhuijzen JA, Hendricksen K. Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer. Eur Urol 2018; 74:369-375. [DOI: 10.1016/j.eururo.2017.05.054] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 05/29/2017] [Indexed: 11/25/2022]
|
22
|
Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun H, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BW, Nyirády P, Szarvas T. P
athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. Int J Cancer 2018; 143:1764-1773. [PMID: 29672836 DOI: 10.1002/ijc.31547] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Revised: 03/12/2018] [Accepted: 03/28/2018] [Indexed: 12/12/2022]
Affiliation(s)
- Henning Reis
- Institute of Pathology, West German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
- German Cancer Consortium (DKTK), Partner Site University Hospital EssenEssen Germany
| | - Kristan E. van der Vos
- Division of Molecular CarcinogenesisNetherlands Cancer Institute ‐ Antoni van Leeuwenhoek HospitalAmsterdam Netherlands
| | - Christian Niedworok
- Department of UrologyWest German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
| | - Thomas Herold
- Institute of Pathology, West German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
- German Cancer Consortium (DKTK), Partner Site University Hospital EssenEssen Germany
| | - Orsolya Módos
- Department of UrologySemmelweis UniversityBudapest Hungary
| | | | - Thomas Hager
- Institute of Pathology, West German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
| | - Marc Ingenwerth
- Institute of Pathology, West German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
| | - Daniël J. Vis
- Division of Molecular CarcinogenesisNetherlands Cancer Institute ‐ Antoni van Leeuwenhoek HospitalAmsterdam Netherlands
| | - Mark A. Behrendt
- Department of Surgical Oncology (Urology)Netherlands Cancer Institute ‐ Antoni van Leeuwenhoek HospitalAmsterdam Netherlands
- Department of Surgery, Division of UrologyUniversity Hospital of BaselBasel Switzerland
| | - Jeroen de Jong
- Department of PathologyNetherlands Cancer Institute ‐ Antoni van Leeuwenhoek HospitalAmsterdam Netherlands
| | - Michiel S. van der Heijden
- Division of Molecular CarcinogenesisNetherlands Cancer Institute ‐ Antoni van Leeuwenhoek HospitalAmsterdam Netherlands
- Department of Medical OncologyNetherlands Cancer Institute ‐ Antoni van Leeuwenhoek HospitalAmsterdam Netherlands
| | | | | | - Marcel Wiesweg
- Department of Medical OncologyWest German Cancer Center, University of Duisburg Essen, University Hospital EssenEssen Germany
| | - Jason Ablat
- Vancouver Prostate CentreUniversity of British ColumbiaVancouver BC Canada
| | - Krzysztof Okon
- Department of PathomorphologyJagiellonian UniversityCracow Poland
| | - Yuri Tolkach
- Institute of Pathology, University of BonnBonn Germany
| | | | - Nikolett Nagy
- Department of UrologySemmelweis UniversityBudapest Hungary
| | - Felix Bremmer
- Institute of Pathology, University of GöttingenGöttingen Germany
| | - Nadine T. Gaisa
- Institute of Pathology, RWTH Aachen UniversityAachen Germany
| | - Piotr Chlosta
- Department of PathomorphologyJagiellonian UniversityCracow Poland
| | - Joerg Kriegsmann
- Center for Histology, Cytology and Molecular Diagnostics TrierTrier Germany
| | - Ilona Kovalszky
- First Institute of Pathology and Experimental Cancer Research, Semmelweis UniversityBudapest Hungary
| | - József Timar
- Second Department of PathologySemmelweis UniversityBudapest Hungary
| | | | | | - Ruth Knüchel
- Institute of Pathology, RWTH Aachen UniversityAachen Germany
| | - Martin Schuler
- German Cancer Consortium (DKTK), Partner Site University Hospital EssenEssen Germany
- Department of Medical OncologyWest German Cancer Center, University of Duisburg Essen, University Hospital EssenEssen Germany
| | - Peter C. Black
- Vancouver Prostate CentreUniversity of British ColumbiaVancouver BC Canada
| | - Herbert Rübben
- Department of UrologyWest German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
| | - Boris A. Hadaschik
- Department of UrologyWest German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
- German Cancer Consortium (DKTK), Partner Site University Hospital EssenEssen Germany
| | - Kurt Werner Schmid
- Institute of Pathology, West German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
- German Cancer Consortium (DKTK), Partner Site University Hospital EssenEssen Germany
| | - Bas W.G. van Rhijn
- Department of Surgical Oncology (Urology)Netherlands Cancer Institute ‐ Antoni van Leeuwenhoek HospitalAmsterdam Netherlands
| | - Péter Nyirády
- Department of UrologySemmelweis UniversityBudapest Hungary
| | - Tibor Szarvas
- Department of UrologyWest German Cancer Center, University of Duisburg‐Essen, University Hospital EssenEssen Germany
- Department of UrologySemmelweis UniversityBudapest Hungary
| |
Collapse
|
23
|
Foerster B, Matin SF, Gupta M, Schweitzer D, Clinton T, Kimura S, Bandini M, Ku JH, Muilwijk T, Monteiro LL, Abufaraj M, Petros F, Bivalacqua TJ, Hendricksen K, Krabbe LM, Egawa S, Briganti A, Joniau S, Kassouf W, Pierorazio PM, van Rhijn BW, Margulis V, Necchi A, Shariat SF. MP18-02 EFFICACY OF PREOPERATIVE CHEMOTHERAPY ON OUTCOMES OF HIGH-RISK UPPER TRACT UROTHELIAL CARCINOMA (UTUC). J Urol 2018. [DOI: 10.1016/j.juro.2018.02.578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
24
|
Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, Takhar M, Erho N, van Kessel KE, Winters B, Douglas J, Lopez FV, Crabb SJ, van Rhijn BW, Franzen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC. MP54-05 PLASTICITY IN THE BIOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
25
|
Bosschieter J, Hentschel A, Savci-Heijink CD, van der Voorn JP, Rozendael RL, Vis AN, van Rhijn BW, Lissenberg-Witte BI, Fransen van de Putte EE, van Moorselaar RJA, Nieuwenhuijzen JA. MP58-18 REPRODUCIBILITY AND PROGNOSTIC VALUE OF THE 1973 AND 2004 WORLD HEALTH ORGANIZATION CLASSIFICATIONS FOR GRADE IN NON-MUSCLE-INVASIVE BLADDER CANCER: A MULTICENTER STUDY IN 328 BLADDER TUMOURS. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Mertens LS, Behrendt MA, Mehta AM, de Jong J, Boot H, Stokkel L, van der Heijden MS, Horenblas S, Moonen LM, Verwaal VJ, Meinhardt W, van Rhijn BW. Long-term survival after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis of urachal cancer. Urol Oncol 2017. [DOI: 10.1016/j.urolonc.2017.06.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Seiler R, Gibb EA, Takhar M, Kessel KV, van Rhijn BW, Winters B, Douglas J, Wang Q, Choeurng V, Erho N, Buerki C, Davicioni E, Sjödahl G, Thalmann GN, Zwarthoff EC, Boormans JL, Dall’Era M, van der Heijden MS, Wright J, Black PC. Plasticity in muscle-invasive bladder cancer before and after cisplatin-based neoadjuvant chemotherapy. Urol Oncol 2017. [DOI: 10.1016/j.urolonc.2017.06.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Seiler R, Al Deen Ashab H, Erho N, van Rhijn BW, Winters B, Douglas J, Van Kessel K, Fransen van de Putte EE, Sommerlad M, Wang Q, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. MP34-01 MOLECULAR SUBTYPES OF MUSCLE INVASIVE BLADDER CANCER ARE RELATED TO BENEFIT FROM NEOADJUVANT CHEMOTHERAPY: DEVELOPMENT OF A SINGLE SAMPLE PATIENT ASSAY. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017; 71:447-461. [DOI: 10.1016/j.eururo.2016.05.041] [Citation(s) in RCA: 1330] [Impact Index Per Article: 190.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 05/30/2016] [Indexed: 12/15/2022]
|
30
|
Seiler R, Winters B, Douglas J, van Rhijn BW, Sjödahl G, Lerner SP, Hoadley KA, North SA, McConkey DJ, Choi W, Kim WY, van Kessel KE, Thalmann GN, Davicioni E, Crabb SJ, Boormans JL, Dall'Era M, Wright JL, Van Der Heijden MS, Black PC. Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.6_suppl.281] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
281 Background: Molecular subtypes of muscle-invasive bladder cancers (MIBC) have recently been discovered based on gene expression. We investigated the impact of different subtyping methods on response to neoadjuvant cisplatin-based chemotherapy (NAC) and developed a single sample model for subtyping. Methods: Transcriptome-wide microarray analysis was conducted on pre-NAC transurethral resection (TUR) specimens of 223 patients with MIBC who received NAC followed by cystectomy at 5 centers. The specimens were classified according to four published methods for molecular subtype (UNC, MDA, TCGA, Lund). Overall survival (OS) for each subtype was compared between NAC patients in this study and non-NAC patients from the provisional TCGA. A genomic classifier (GSC) was trained to predict subtype in a single sample model and validated in independent NAC (2 centers) and non-NAC datasets. Results: The models generated subtype calls similar to previously published ratios. Concordance of a given subtype between the different methods was high. Luminal tumors had the best OS independent of NAC. Patients with tumors classified as UNC basal, MDA basal and TCGA cluster III experienced the greatest improvement in OS after NAC compared to surgery alone. Tumors assigned as UNC claudin-low had the worst OS irrespective of treatment regimen (p=0.005). GSC accurately predicted four classes (luminal, luminal-infiltrated, basal, claudin-low) and the differential impact of a basal subtype on patient OS in NAC (3-yr survival of 75.2%; p=0.001) and non-NAC (3-yr survival of 42.4%; p=0.014) cohorts could be validated. Conclusions: The benefit of NAC varies between molecular subtypes. The good prognosis of luminal/cluster I tumors could not be improved with NAC, which suggests these patients may be managed best with surgery alone. The prognosis of patients with basal tumors improved the most when treated with NAC compared to surgery alone. Poor OS of claudin-low tumors even after NAC implies that these tumors are resistant to cisplatin-based chemotherapy, and these patients should be included in protocols investigating alternative treatment options like immunotherapy. Further validation prior to clinical implementation is needed.
Collapse
Affiliation(s)
- Roland Seiler
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Brian Winters
- Department of Urology, University of Washington School of Medicine, Seattle, WA
| | - James Douglas
- University of Southampton, Southampton, United Kingdom
| | - Bas W.G. van Rhijn
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Gottfrid Sjödahl
- Division of Urological Research, Department of Translational Medicine, Malmo, Sweden
| | | | | | - Scott A. North
- Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | | | - Woonyoung Choi
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - William Y. Kim
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| | - Kim E.M van Kessel
- Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | | | | | - Simon J. Crabb
- Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom
| | - Joost L Boormans
- Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Marc Dall'Era
- UC Davis Comprehensive Cancer Center, Sacramento, CA
| | | | | | | |
Collapse
|
31
|
Hermans TJ, Fransen van de Putte EE, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, de Wit R, Beerepoot LV, Verhoeven RH, van Rhijn BW. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—Results of a nationwide population-based study. Eur J Cancer 2016; 69:1-8. [DOI: 10.1016/j.ejca.2016.09.015] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Revised: 09/01/2016] [Accepted: 09/13/2016] [Indexed: 12/01/2022]
|
32
|
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. J Urol 2016; 196:1627-1633. [DOI: 10.1016/j.juro.2016.06.017] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2016] [Indexed: 11/15/2022]
Affiliation(s)
| | - Siamak Daneshmand
- University of Southern California-Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
| | - Daniel Canter
- Fox Chase Cancer Center, Einstein Health Network and Urologic Institute of Southeastern Pennsylvania, Philadelphia, Pennsylvania
| | - Yair Lotan
- University of Texas Southwestern Medical Center, Dallas, Texas
| | - Peter C. Black
- Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Hamidreza Abdi
- Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Bas W.G. van Rhijn
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | | | - Piotr Zareba
- McMaster University and Juravinski Hospital, Hamilton, Ontario, Canada
| | - Ilmari Koskinen
- Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | | | | | | | - Peter J. Boström
- Turku University Hospital and University of Turku, Turku, Finland
| | - Bobby Shayegan
- McMaster University and Juravinski Hospital, Hamilton, Ontario, Canada
| | | |
Collapse
|
33
|
Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA. Microhematuria assessment an IBCN consensus—Based upon a critical review of current guidelines. Urol Oncol 2016; 34:437-51. [DOI: 10.1016/j.urolonc.2016.05.030] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 05/26/2016] [Accepted: 05/26/2016] [Indexed: 10/21/2022]
|
34
|
Hermans TJ, Mertens LS, van Rhijn BW. Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides. Eur Urol 2016; 69:1156-7. [DOI: 10.1016/j.eururo.2016.02.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Gild P, Schmid M, Cumberbatch M, Dobruch J, Gontero P, Mertens LS, Necchi A, Noon A, Preto M, van Rhijn BW, Roupret M, Seiler R, Seisen T, Shariat SF, Aziz A, Chun FK, Xylinas E, Rink M. PD27-06 THE IMPACT OF CIGARETTE SMOKING AND SMOKING CESSATION ON ONCOLOGICAL AGGRESSIVENESS AT RADICAL CYSTECTOMY – A PROSPECTIVE, EUROPEAN, MULTICENTER STUDY OF THE EAU YOUNG ACADEMIC UROLOGISTS (YAU) BLADDER CANCER WORKING GROUP. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Fransen van de Putte EE, Pos FJ, Doodeman B, van Rhijn BW, van der Laan E, Van Der Heijden MS, Kerst JM, Horenblas S, Bergman AM. A phase I study of chemoradiation with weekly panitumumab following neoadjuvant chemotherapy and pelvic lymph node dissection as an organ preserving treatment of invasive bladder cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.2_suppl.392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
392 Background: Radical Cystectomy (RC) is the standard treatment of Invasive Bladder Cancer (IBC). Although organ sparing, external beam Radiation Treatment (RT) alone is considered inferior to RC. Since the Epidermal Growth Factor receptor (EGFr) is frequently overexpressed in IBC, combined EGFr inhibition by Panitumumab (P) and RT might improve treatment outcome. In this study, the safety and efficacy of concurrent RT and P (RT/P) following Neoadjuvant Chemotherapy (NAC) and Pelvic Lymph Node Dissection (PLND) was evaluated. Methods: cT2-4N0-2M0 or cT1N1-2M0 bladder cancer patients were enrolled in the study. NAC consisted of a maximum of 4 cycles platinum-based chemotherapy. cN0 patients received NAC after PLND, while cN+ patients (confirmed by fine needle aspiration) received NAC prior to PLND. RT/P consisted of concurrent P (7 weekly doses of 2.5 mg/kg) and bladder RT (66Gy in 33 fractions). Primary end-points were treatment-related toxicity and complete clinical response (CR) assessed by Computed Tomography and cystoscopy 3 months after therapy completion. Partial response (PR) was defined as cT < 2N0. Results: A total of 31 patients were included (mean age: 60±10 years), 3/31 patients were cN1-2. Three patients discontinued NAC after 3 cycles due to toxicity. After NAC (24 cisplatin-based and 7 gemcitabine/carboplatin) 13 (41.9%) patients had remaining visible disease. All patients completed RT, while 4/31 patients terminated P prematurely (2-6 doses) due to toxicity. Preliminary response results after RT/P were available for 29/31 patients. Twenty-six/29 (89.7%) patients had a CR, 3 patients PR (10.3%) of which 2 were treated with transurethral resection and intravesical treatment (TaG1-2) and 1 patient underwent immediate cystectomy after histologic confirmation of T1G3. Conclusions: These preliminary results suggest that concurrent P and RT following NAC and PLND is an organ-preserving option for IBC. Toxicity, EGFr expression, mutational status and long-term oncologic outcomes have to be awaited. Clinical trial information: NL31148.031.10.
Collapse
Affiliation(s)
| | - Floris J. Pos
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Barry Doodeman
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Bas W.G. van Rhijn
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Elsbeth van der Laan
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | | | - Jan M. Kerst
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Simon Horenblas
- The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Andre M. Bergman
- Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| |
Collapse
|
37
|
Fransen van de Putte EE, Hermans TJ, van Werkhoven E, Mertens LS, Meijer RP, Bex A, van der Poel HG, van Rhijn BW, Horenblas S. PD31-07 DIFFERENCES IN LYMPH NODE COUNT AT RADICAL CYSTECTOMY WITH A STANDARDIZED SURGICAL TEMPLATE DO NOT INFLUENCE LONG-TERM SURVIVAL FOR BLADDER CANCER. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.2092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Fransen van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW. PD31-11 NEOADJUVANT DOSE-DENSE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.2096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
van der Heijden MS, van Rhijn BW. The Molecular Background of Urothelial Cancer: Ready for Action? Eur Urol 2015; 67:202-3. [DOI: 10.1016/j.eururo.2014.07.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Accepted: 07/16/2014] [Indexed: 02/09/2023]
|
40
|
van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, Shariat SF, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeney LA. Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. Urol Oncol 2014; 32:1078-87. [DOI: 10.1016/j.urolonc.2014.07.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Revised: 07/02/2014] [Accepted: 07/03/2014] [Indexed: 10/24/2022]
|
41
|
Djajadiningrat RS, van Werkhoven E, Meinhardt W, van Rhijn BW, Bex A, van der Poel HG, Horenblas S. Penile Sparing Surgery for Penile Cancer—Does it Affect Survival? J Urol 2014; 192:120-5. [DOI: 10.1016/j.juro.2013.12.038] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2013] [Indexed: 01/09/2023]
Affiliation(s)
- Rosa S. Djajadiningrat
- Departments of Urology and Biometrics (EvW), The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands
| | - Erik van Werkhoven
- Departments of Urology and Biometrics (EvW), The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands
| | - Wim Meinhardt
- Departments of Urology and Biometrics (EvW), The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands
| | - Bas W.G. van Rhijn
- Departments of Urology and Biometrics (EvW), The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands
| | - Axel Bex
- Departments of Urology and Biometrics (EvW), The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands
| | - Henk G. van der Poel
- Departments of Urology and Biometrics (EvW), The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands
| | - Simon Horenblas
- Departments of Urology and Biometrics (EvW), The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
42
|
Mertens LS, Meijer RP, de Vries RR, Nieuwenhuijzen JA, van der Poel HG, Bex A, van Rhijn BW, Meinhardt W, Horenblas S. Prostate Sparing Cystectomy for Bladder Cancer: 20-Year Single Center Experience. J Urol 2014; 191:1250-5. [DOI: 10.1016/j.juro.2013.11.031] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/14/2013] [Indexed: 11/25/2022]
Affiliation(s)
- Laura S. Mertens
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | - Richard P. Meijer
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Remco R. de Vries
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- Department of Urology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands
| | | | - Henk G. van der Poel
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | - Axel Bex
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | - Bas W.G. van Rhijn
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | - Wim Meinhardt
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | - Simon Horenblas
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| |
Collapse
|
43
|
Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. BJU Int 2014; 114:67-74. [DOI: 10.1111/bju.12447] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Laura S. Mertens
- Department of Urology; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - Richard P. Meijer
- Department of Urology; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
- Department of Urology; University Medical Center; Utrecht The Netherlands
| | - Wim Meinhardt
- Department of Urology; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - Henk G. van der Poel
- Department of Urology; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - Axel Bex
- Department of Urology; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - J. Martijn Kerst
- Department of Medical Oncology; The Netherlands Cancer Institute; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - Michiel S. van der Heijden
- Department of Medical Oncology; The Netherlands Cancer Institute; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - Andries M. Bergman
- Department of Medical Oncology; The Netherlands Cancer Institute; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - Simon Horenblas
- Department of Urology; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| | - Bas W.G. van Rhijn
- Department of Urology; Antoni van Leeuwenhoek Hospital; Amsterdam The Netherlands
| |
Collapse
|
44
|
|
45
|
van Rhijn BW, Stakhovskyi O, Margel D, van der Kwast T, Bostrom PJ, Thoms J, Bristow RG, Milosevic M, Fleshner NE, Jewett MA, Bapat B, Kim WJ, Zlotta AR. 1075 HEAT SHOCK PROTEIN 70 (HSP70) AND FGFR3 IN NON MUSCLE INVASIVE BLADDER CANCER TREATED WITH BCG GENE EXPRESSION AND PROTEIN EXPRESSION ANALYSIS USING 2 DIFFERENT VALIDATION COHORTS. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.1181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Stakhovskyi O, Margel D, van der Kwast T, van Rhijn BW, Bostrom PJ, Thoms J, Bristow RG, Fleshner NE, Jewett MA, Bapat B, Zlotta AR. 551 HEAT SHOCK PROTEIN 70 (HSP70) AS A RECURRENCE MARKER FOR PT1 BLADDER CANCER. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Bostrom PJ, Thoms J, van Rhijn BW, Ahmed O, Stakhovskyi O, Margel D, Evans A, Mirtti T, Sykes J, Pintillie M, Laato M, Milosevic M, Zlotta AR, Bristow RG. 1417 HYPOXIA IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOME IN UROTHELIAL BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.1868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Meijer RP, van Rhijn BW. A Plea for Long-Term Surveillance in Bacillus Calmette-Guérin–Treated Non–Muscle-Invasive Bladder Cancer. Eur Urol 2012; 61:508-9. [DOI: 10.1016/j.eururo.2011.11.052] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Accepted: 11/28/2011] [Indexed: 11/28/2022]
|
49
|
Affiliation(s)
- Bas W.G. van Rhijn
- Division of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| |
Collapse
|
50
|
van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA, Zlotta AR. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol 2012; 61:378-84. [DOI: 10.1016/j.eururo.2011.10.026] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2011] [Accepted: 10/14/2011] [Indexed: 10/15/2022]
|